Authors: Mariadelina Simeoni Ramona Nicotera Maria Colao Maria Lucia Citraro Elena Pelagi Annamaria Cerantonio Nicola Comi Giuseppe Coppolino Giorgio Fuiano
Publish Date: 2015/10/05
Volume: 48, Issue: 2, Pages: 229-237
Abstract
Nondiabetic glomerulonephritis is a frequent cause of endstage renal disease The use of renin–angiotensin–aldosterone system blockers is a fundamental therapeutic approach However converting enzyme inhibitors ACEis and angiotensin receptor blockers do not always achieve the desired target of proteinuria The induction of the prorenin and renin upregulation is a possible explanation Aliskiren is the first drug acting as direct inhibitor of plasmatic renin activity also able to interfere with the prorenin and renin profibrotic escape We aimed at reviewing the literature for the assessment of potential efficacy and safety of aliskiren in the treatment of nondiabetic glomerulonephritis The data on this topic are limited however we concluded for a possible usefulness of aliskiren The renal safety profile appears potentially acceptable in nondiabetic patients although extreme carefulness particularly with respect to longterm renal and cardiovascular tolerability is recommended
Keywords: